210 related articles for article (PubMed ID: 36228414)
41. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C; Hu Y; Zhou B; Fernandez-Salas E; Yang CY; Liu L; McEachern D; Przybranowski S; Wang M; Stuckey J; Meagher J; Bai L; Chen Z; Lin M; Yang J; Ziazadeh DN; Xu F; Hu J; Xiang W; Huang L; Li S; Wen B; Sun D; Wang S
J Med Chem; 2018 Aug; 61(15):6685-6704. PubMed ID: 30019901
[TBL] [Abstract][Full Text] [Related]
42. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
43. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
44. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
45. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
46. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.
Zhu CL; Luo X; Tian T; Rao Z; Wang H; Zhou Z; Mi T; Chen D; Xu Y; Wu Y; Che J; Zhou Y; Li J; Dong X
Eur J Med Chem; 2022 Aug; 238():114459. PubMed ID: 35635954
[TBL] [Abstract][Full Text] [Related]
47. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.
Bashore FM; Foley CA; Ong HW; Rectenwald JM; Hanley RP; Norris-Drouin JL; Cholensky SH; Mills CA; Pearce KH; Herring LE; Kireev D; Frye SV; James LI
ACS Chem Biol; 2023 Mar; 18(3):494-507. PubMed ID: 36877831
[TBL] [Abstract][Full Text] [Related]
48. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
[TBL] [Abstract][Full Text] [Related]
49. Discovery of Bisubstrate Inhibitors for Protein N-Terminal Methyltransferase 1.
Chen D; Dong G; Noinaj N; Huang R
J Med Chem; 2019 Apr; 62(7):3773-3779. PubMed ID: 30883119
[TBL] [Abstract][Full Text] [Related]
50. The comprehensive analysis of the prognostic and functional role of N-terminal methyltransferases 1 in pan-cancer.
Tan L; Li W; Su Q
PeerJ; 2023; 11():e16263. PubMed ID: 37901469
[TBL] [Abstract][Full Text] [Related]
51. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
52. Chemoproteomic Study Uncovers HemK2/KMT9 As a New Target for NTMT1 Bisubstrate Inhibitors.
Chen D; Meng Y; Yu D; Noinaj N; Cheng X; Huang R
ACS Chem Biol; 2021 Jul; 16(7):1234-1242. PubMed ID: 34192867
[TBL] [Abstract][Full Text] [Related]
53. A practical "preTACs-cytoblot" platform accelerates the streamlined development of PROTAC-based protein degraders.
Rao Z; Li K; Hong J; Chen D; Ding B; Jiang L; Qi X; Hu J; Yang B; He Q; Dong X; Cao J; Zhu CL
Eur J Med Chem; 2023 May; 251():115248. PubMed ID: 36905918
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
56. Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors.
Duan H; Zhang J; Gui R; Lu Y; Pang A; Chen B; Shen L; Yu H; Li J; Xu T; Wang Y; Yao X; Zhang B; Lin N; Dong X; Zhou Y; Che J
J Med Chem; 2024 Jun; ():. PubMed ID: 38913763
[TBL] [Abstract][Full Text] [Related]
57. The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader.
Xie H; Liang JJ; Wang YL; Hu TX; Wang JY; Yang RH; Yan JK; Zhang QR; Xu X; Liu HM; Ke Y
Eur J Med Chem; 2020 Oct; 204():112512. PubMed ID: 32736229
[TBL] [Abstract][Full Text] [Related]
58. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
60. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Shirasaki R; Matthews GM; Gandolfi S; de Matos Simoes R; Buckley DL; Raja Vora J; Sievers QL; Brüggenthies JB; Dashevsky O; Poarch H; Tang H; Bariteau MA; Sheffer M; Hu Y; Downey-Kopyscinski SL; Hengeveld PJ; Glassner BJ; Dhimolea E; Ott CJ; Zhang T; Kwiatkowski NP; Laubach JP; Schlossman RL; Richardson PG; Culhane AC; Groen RWJ; Fischer ES; Vazquez F; Tsherniak A; Hahn WC; Levy J; Auclair D; Licht JD; Keats JJ; Boise LH; Ebert BL; Bradner JE; Gray NS; Mitsiades CS
Cell Rep; 2021 Jan; 34(1):108532. PubMed ID: 33406420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
